GSK Statistics
Total Valuation
GSK has a market cap or net worth of $103.40 billion. The enterprise value is $124.16 billion.
Important Dates
The last earnings date was Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
GSK has 4.02 billion shares outstanding. The number of shares has decreased by -1.13% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.02B |
| Shares Change (YoY) | -1.13% |
| Shares Change (QoQ) | -0.29% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 86.84% |
| Float | 3.86B |
Valuation Ratios
The trailing PE ratio is 13.43 and the forward PE ratio is 10.14.
| PE Ratio | 13.43 |
| Forward PE | 10.14 |
| PS Ratio | 2.39 |
| Forward PS | 2.91 |
| PB Ratio | 4.49 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 11.95 |
| P/OCF Ratio | 10.12 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.22, with an EV/FCF ratio of 14.35.
| EV / Earnings | 16.13 |
| EV / Sales | 2.87 |
| EV / EBITDA | 8.22 |
| EV / EBIT | 9.49 |
| EV / FCF | 14.35 |
Financial Position
The company has a current ratio of 0.79, with a Debt / Equity ratio of 1.10.
| Current Ratio | 0.79 |
| Quick Ratio | 0.51 |
| Debt / Equity | 1.10 |
| Debt / EBITDA | 1.64 |
| Debt / FCF | 2.92 |
| Interest Coverage | 14.94 |
Financial Efficiency
Return on equity (ROE) is 40.91% and return on invested capital (ROIC) is 26.70%.
| Return on Equity (ROE) | 40.91% |
| Return on Assets (ROA) | 10.02% |
| Return on Invested Capital (ROIC) | 26.70% |
| Return on Capital Employed (ROCE) | 24.49% |
| Weighted Average Cost of Capital (WACC) | 5.56% |
| Revenue Per Employee | $647,583 |
| Profits Per Employee | $115,154 |
| Employee Count | 66,841 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.46 |
Taxes
In the past 12 months, GSK has paid $1.43 billion in taxes.
| Income Tax | 1.43B |
| Effective Tax Rate | 14.54% |
Stock Price Statistics
The stock price has increased by +29.51% in the last 52 weeks. The beta is 0.35, so GSK's price volatility has been lower than the market average.
| Beta (5Y) | 0.35 |
| 52-Week Price Change | +29.51% |
| 50-Day Moving Average | 55.68 |
| 200-Day Moving Average | 48.00 |
| Relative Strength Index (RSI) | 34.23 |
| Average Volume (20 Days) | 4,236,490 |
Short Selling Information
The latest short interest is 15.45 million, so 0.77% of the outstanding shares have been sold short.
| Short Interest | 15.45M |
| Short Previous Month | 12.38M |
| Short % of Shares Out | 0.77% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.67 |
Income Statement
In the last 12 months, GSK had revenue of $43.29 billion and earned $7.70 billion in profits. Earnings per share was $1.88.
| Revenue | 43.29B |
| Gross Profit | 31.54B |
| Operating Income | 13.08B |
| Pretax Income | 9.82B |
| Net Income | 7.70B |
| EBITDA | 15.10B |
| EBIT | 13.08B |
| Earnings Per Share (EPS) | $1.88 |
Full Income StatementBalance Sheet
The company has $4.55 billion in cash and $25.24 billion in debt, with a net cash position of -$20.69 billion or -$5.15 per share.
| Cash & Cash Equivalents | 4.55B |
| Total Debt | 25.24B |
| Net Cash | -20.69B |
| Net Cash Per Share | -$5.15 |
| Equity (Book Value) | 23.01B |
| Book Value Per Share | 5.86 |
| Working Capital | -6.16B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $10.22 billion and capital expenditures -$1.80 billion, giving a free cash flow of $8.65 billion.
| Operating Cash Flow | 10.22B |
| Capital Expenditures | -1.80B |
| Depreciation & Amortization | 2.07B |
| Net Borrowing | 723.07M |
| Free Cash Flow | 8.65B |
| FCF Per Share | $2.15 |
Full Cash Flow StatementMargins
Gross margin is 72.87%, with operating and profit margins of 30.22% and 17.78%.
| Gross Margin | 72.87% |
| Operating Margin | 30.22% |
| Pretax Margin | 22.69% |
| Profit Margin | 17.78% |
| EBITDA Margin | 34.88% |
| EBIT Margin | 30.22% |
| FCF Margin | 19.98% |
Dividends & Yields
This stock pays an annual dividend of $1.75, which amounts to a dividend yield of 3.41%.
| Dividend Per Share | $1.75 |
| Dividend Yield | 3.41% |
| Dividend Growth (YoY) | 13.97% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 93.08% |
| Buyback Yield | 1.13% |
| Shareholder Yield | 4.51% |
| Earnings Yield | 7.44% |
| FCF Yield | 8.37% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 1.83% |
| EPS Growth Forecast (5Y) | 3.92% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
The last stock split was on July 19, 2022. It was a reverse split with a ratio of 1:1.25.
| Last Split Date | Jul 19, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:1.25 |
Scores
GSK has an Altman Z-Score of 2.09 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.09 |
| Piotroski F-Score | 7 |
